>Go!
NEWS SEARCH

07.11.2017 | Investors

See America Furthers The Fight Against Preventable Blindness With #EyePic Campaign

Allergan partners with Milo Ventimiglia, Victor Cruz, and Alexandra Daddario to promote vision health and raise money for the American Foundation for the Blind

DUBLIN, July 11, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a global leader in eye care for nearly 70 years, today unveiled #EyePic, an exciting new online awareness campaign as part of the See America initiative to fight preventable blindness and visual impairment in the United States. #EyePic will use the power of social media to broaden awareness of preventable blindness, promote discussion around eye health and ultimately encourage all Americans to visit their eye doctors for comprehensive eye exams.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8134051-allergan-see-america-eyepic-campaign/

Allergan has partnered with television star Milo Ventimiglia, professional football player Victor Cruz, and actress Alexandra Daddario to engage with their friends and followers through entertaining video content and launch #EyePic by posting a photo of their eyes and tagging two friends to do the same. For every #EyePic posted, See America will donate $10 to the American Foundation for the Blind*, a national non-profit founded in 1921 to better the quality of life for Americans already suffering with vision loss.  

"Sight is one of life's most amazing and delicate gifts," said Jag Dosanjh, SVP of US Eye Care at Allergan. "We're launching #EyePic on social media to spread the word about preventable blindness, in a forum where people can easily join the fight. With the help of Milo, Victor, Alexandra and the many Americans who will be posting their own #EyePic, we will encourage proactive eye care and communicate important facts about preventable blindness in America."

Not all blindness is preventable; today in the United States, there are more than 20 million Americans living with vision loss1. By supporting the American Foundation for the Blind's vital programs and services, Allergan is helping to create a more inclusive society for Americans with visual impairments.

"We are grateful for Allergan's support," said Kirk Adams, President and CEO of the American Foundation for the Blind. "The American Foundation for the Blind is committed to creating a world with no limits for millions of Americans who are blind or visually impaired, like myself; and we are heartened that Allergan is supporting our mission."

To get involved with #EyePic, follow three easy steps:
1. Post a picture of your eyes
2. Add #EyePic
3. Tag two friends to do the same

To watch the videos and learn more about #EyePic, visit www.SeeAmerica.vision.

*up to $50,000

About See America

Allergan, a global leader in eye care for nearly 70 years, recently launched See America to fight against preventable blindness and vision impairment in America. See America has set out to make vision health a priority across the U.S., increase awareness of diseases that cause preventable blindness, and bring critical access to vision care to those who need it most. To find out more about See America, visit www.SeeAmerica.vision

About The American Foundation For The Blind

The American Foundation for the Blind (AFB) is a national nonprofit that expands possibilities for people with vision loss. AFB fulfills its mission by broadening access to technology; elevating the quality of information and tools for the professionals who serve people with vision loss; and promoting independent and healthy living for people with vision loss by providing them and their families with relevant and timely resources. Headquartered in New York, AFB is proud to house the Helen Keller Archives & Gallery and honor the more than 40 years that Helen Keller worked tirelessly for AFB.

About Allergan Plc.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Allergan Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

References

1 National Center for Health Statistics, National Health Interview Survey (NHIS), 2015, www.cdc.gov/nchs/nhis.htm.

Behind the Scenes with Milo Ventimiglia

 

Behind the Scenes with Milo Ventimiglia

 

Behind the Scenes with Milo Ventimiglia

 

View original content:http://www.prnewswire.com/news-releases/see-america-furthers-the-fight-against-preventable-blindness-with-eyepic-campaign-300485757.html

SOURCE Allergan

Allergan: Investors: Daphne Karydas, (862) 261-8006; Media: Mark Marmur, (862) 261-7558; Suzanne Jacobson, (201) 427-8879

Media Contacts
Mark Marmur
Global Corporate Media Relations
+1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
+1 (201) 427-8762
Janet Kettels
International Product Media Relations
+44 773 850 6476

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488